vs
巴诺书店（NE）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是巴诺书店的1.0倍（$772.1M vs $764.4M），Revvity净利率更高（12.7% vs 11.3%，领先1.4%），Revvity同比增速更快（5.9% vs -17.6%），Revvity自由现金流更多（$161.8M vs $35.4M），过去两年巴诺书店的营收复合增速更高（9.5% vs 9.0%）
巴诺书店是美国知名连锁图书零售企业，拥有全美数量最多的实体零售网点，目前在美国境内共运营超过700家线下门店，为消费者提供各类书籍、文创产品及相关文化消费服务。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
NE vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.0倍
$764.4M
营收增速更快
RVTY
高出23.4%
-17.6%
净利率更高
RVTY
高出1.4%
11.3%
自由现金流更多
RVTY
多$126.4M
$35.4M
两年增速更快
NE
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $764.4M | $772.1M |
| 净利润 | $86.6M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 5.6% | 14.5% |
| 净利率 | 11.3% | 12.7% |
| 营收同比 | -17.6% | 5.9% |
| 净利润同比 | -10.4% | 3.9% |
| 每股收益（稀释后） | $0.54 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NERVTY
| Q4 25 | $764.4M | $772.1M | ||
| Q3 25 | $798.0M | $698.9M | ||
| Q2 25 | $848.7M | $720.3M | ||
| Q1 25 | $874.5M | $664.8M | ||
| Q4 24 | $927.3M | $729.4M | ||
| Q3 24 | $800.5M | $684.0M | ||
| Q2 24 | $692.8M | $691.7M | ||
| Q1 24 | $637.1M | $649.9M |
净利润NERVTY
| Q4 25 | $86.6M | $98.4M | ||
| Q3 25 | $-21.1M | $46.7M | ||
| Q2 25 | $42.9M | $53.9M | ||
| Q1 25 | $108.3M | $42.2M | ||
| Q4 24 | $96.6M | $94.6M | ||
| Q3 24 | $61.2M | $94.4M | ||
| Q2 24 | $195.0M | $55.4M | ||
| Q1 24 | $95.5M | $26.0M |
毛利率NERVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率NERVTY
| Q4 25 | 5.6% | 14.5% | ||
| Q3 25 | 6.3% | 11.7% | ||
| Q2 25 | 15.9% | 12.6% | ||
| Q1 25 | 21.4% | 10.9% | ||
| Q4 24 | 18.4% | 16.3% | ||
| Q3 24 | 14.4% | 14.3% | ||
| Q2 24 | 30.3% | 12.4% | ||
| Q1 24 | 16.9% | 6.8% |
净利率NERVTY
| Q4 25 | 11.3% | 12.7% | ||
| Q3 25 | -2.6% | 6.7% | ||
| Q2 25 | 5.1% | 7.5% | ||
| Q1 25 | 12.4% | 6.4% | ||
| Q4 24 | 10.4% | 13.0% | ||
| Q3 24 | 7.6% | 13.8% | ||
| Q2 24 | 28.1% | 8.0% | ||
| Q1 24 | 15.0% | 4.0% |
每股收益（稀释后）NERVTY
| Q4 25 | $0.54 | $0.86 | ||
| Q3 25 | $-0.13 | $0.40 | ||
| Q2 25 | $0.27 | $0.46 | ||
| Q1 25 | $0.67 | $0.35 | ||
| Q4 24 | $0.56 | $0.77 | ||
| Q3 24 | $0.40 | $0.77 | ||
| Q2 24 | $1.34 | $0.45 | ||
| Q1 24 | $0.66 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $471.4M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.5B | $7.3B |
| 总资产 | $7.5B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NERVTY
| Q4 25 | $471.4M | $919.9M | ||
| Q3 25 | $477.9M | $931.4M | ||
| Q2 25 | $338.2M | $991.8M | ||
| Q1 25 | $303.8M | $1.1B | ||
| Q4 24 | $247.3M | $1.2B | ||
| Q3 24 | $391.9M | $1.2B | ||
| Q2 24 | $162.9M | $2.0B | ||
| Q1 24 | $212.5M | $1.7B |
股东权益NERVTY
| Q4 25 | $4.5B | $7.3B | ||
| Q3 25 | $4.5B | $7.4B | ||
| Q2 25 | $4.6B | $7.6B | ||
| Q1 25 | $4.7B | $7.6B | ||
| Q4 24 | $4.7B | $7.7B | ||
| Q3 24 | $4.7B | $7.9B | ||
| Q2 24 | $4.0B | $7.9B | ||
| Q1 24 | $3.9B | $7.8B |
总资产NERVTY
| Q4 25 | $7.5B | $12.2B | ||
| Q3 25 | $7.6B | $12.1B | ||
| Q2 25 | $7.7B | $12.4B | ||
| Q1 25 | $7.9B | $12.4B | ||
| Q4 24 | $8.0B | $12.4B | ||
| Q3 24 | $8.0B | $12.8B | ||
| Q2 24 | $5.6B | $13.4B | ||
| Q1 24 | $5.4B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $187.1M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $35.4M | $161.8M |
| 自由现金流率自由现金流/营收 | 4.6% | 21.0% |
| 资本支出强度资本支出/营收 | 19.9% | 2.6% |
| 现金转化率经营现金流/净利润 | 2.16× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $432.2M | $509.4M |
8季度趋势，按日历期对齐
经营现金流NERVTY
| Q4 25 | $187.1M | $182.0M | ||
| Q3 25 | $277.1M | $138.5M | ||
| Q2 25 | $216.4M | $134.3M | ||
| Q1 25 | $271.1M | $128.2M | ||
| Q4 24 | $136.2M | $174.2M | ||
| Q3 24 | $283.8M | $147.9M | ||
| Q2 24 | $106.8M | $158.6M | ||
| Q1 24 | $128.7M | $147.6M |
自由现金流NERVTY
| Q4 25 | $35.4M | $161.8M | ||
| Q3 25 | $139.5M | $120.0M | ||
| Q2 25 | $99.8M | $115.5M | ||
| Q1 25 | $157.5M | $112.2M | ||
| Q4 24 | $-4.4M | $149.8M | ||
| Q3 24 | $156.8M | $125.6M | ||
| Q2 24 | $-34.3M | $136.6M | ||
| Q1 24 | $-37.9M | $129.7M |
自由现金流率NERVTY
| Q4 25 | 4.6% | 21.0% | ||
| Q3 25 | 17.5% | 17.2% | ||
| Q2 25 | 11.8% | 16.0% | ||
| Q1 25 | 18.0% | 16.9% | ||
| Q4 24 | -0.5% | 20.5% | ||
| Q3 24 | 19.6% | 18.4% | ||
| Q2 24 | -4.9% | 19.7% | ||
| Q1 24 | -6.0% | 20.0% |
资本支出强度NERVTY
| Q4 25 | 19.9% | 2.6% | ||
| Q3 25 | 17.3% | 2.6% | ||
| Q2 25 | 13.7% | 2.6% | ||
| Q1 25 | 13.0% | 2.4% | ||
| Q4 24 | 15.2% | 3.4% | ||
| Q3 24 | 15.9% | 3.3% | ||
| Q2 24 | 20.4% | 3.2% | ||
| Q1 24 | 26.2% | 2.7% |
现金转化率NERVTY
| Q4 25 | 2.16× | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | 5.05× | 2.49× | ||
| Q1 25 | 2.50× | 3.03× | ||
| Q4 24 | 1.41× | 1.84× | ||
| Q3 24 | 4.64× | 1.57× | ||
| Q2 24 | 0.55× | 2.87× | ||
| Q1 24 | 1.35× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NE
| Floaters | $559.8M | 73% |
| Jackups | $145.5M | 19% |
| Service Other | $59.1M | 8% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
